Advertisement
U.S. markets open in 4 hours 46 minutes
  • S&P Futures

    5,209.75
    -5.00 (-0.10%)
     
  • Dow Futures

    39,229.00
    +6.00 (+0.02%)
     
  • Nasdaq Futures

    18,192.75
    -38.75 (-0.21%)
     
  • Russell 2000 Futures

    2,046.50
    -3.30 (-0.16%)
     
  • Crude Oil

    82.53
    -0.19 (-0.23%)
     
  • Gold

    2,153.20
    -11.10 (-0.51%)
     
  • Silver

    25.00
    -0.26 (-1.03%)
     
  • EUR/USD

    1.0847
    -0.0029 (-0.27%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.50
    +0.17 (+1.19%)
     
  • GBP/USD

    1.2685
    -0.0044 (-0.34%)
     
  • USD/JPY

    150.4830
    +1.3850 (+0.93%)
     
  • Bitcoin USD

    63,754.93
    -3,934.63 (-5.81%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,729.54
    +6.99 (+0.09%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Express Scripts to maintain availability of AbbVie's hep C drug

Oct 28 (Reuters) - Pharmacy benefit manager Express Scripts Holding Co said the potential risk of liver injury from AbbVie' hepatitis C treatments has not impacted the availability of the treatment for patients for whom it is safe and effective.

The Food and Drug Administration said last week AbbVie Inc had identified cases of hepatic decompensation and liver failure in patients with liver cirrhosis who were taking the medicines.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D'Souza)

Advertisement